Skip to main content

Our Journey
Our Technology
Pipeline

Leadership
Investors
Get in Touch

Press Releases

Overview
Press Releases
Events
Presentations
Corporate Governance
Analyst Coverage
Stock Information
SEC Filings
Investor FAQs

Investor Contact

Loraine Spreen
+1-857-277-4842
loraine.spreen@kalarx.com

Press Releases

Keyword Search

Year

Mar 18, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Mar 16, 2021

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna

Mar 02, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March

Feb 25, 2021

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Feb 18, 2021

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

Feb 17, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Feb 16, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Jan 20, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jan 07, 2021

Kala Pharmaceuticals Announces Availability of EYSUVIS™ for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Jan 04, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January

Our Journey
Our Technology
Pipeline
Leadership
- Management Team
- Board of Directors
Investors
Get in Touch

©2021 Kala Pharmaceuticals All rights reserved. AMPPLIFY is a trademark and INVELTYS is a registered trademark of Kala Pharmaceuticals.
US-INV-1900184 January 2021

Terms of Use Privacy Statement Accessibility Policy